Higher persistency rates be see among osteoporosis patients taking FOSAMAX(R) Once Weekly (alendronate) therapy than were seen among patients taking ibandronate once monthly or once weekly risedronate therapies, according to grades from two blotchy outcome inspection conduct via Merck & Co., Inc. that compare persistency rates of weekly versus monthly oral bisphosophate dose [...]
Entries from April 2009
Higher Persistency Rates Seen With FOSAMAX(R) Once Weekly Therapies Compared To Other Weekly And Monthly Oral Bisphosphonates
April 14th, 2009 · No Comments
Tags: health md web womans
